The race to combat Ebola is a global effort, and the recent funding awarded to three vaccine developers is a crucial step in the right direction. However, the complexities of the situation in the Democratic Republic of the Congo (DRC) and Uganda, where the Bundibugyo strain of Ebola is spreading, cannot be understated. The challenges of setting up trials in conflict-affected regions and the need for comprehensive action to prevent future outbreaks are key issues that demand attention.
Personally, I think the funding for vaccine development is a necessary step, but it is just one piece of the puzzle. The real challenge lies in the complexities of the affected regions and the need for a holistic approach to combat Ebola. What makes this particularly fascinating is the interplay between security issues, conflict, and the development of vaccines and treatments. It raises a deeper question: how can we effectively address the challenges of Ebola outbreaks in regions affected by conflict?
One thing that immediately stands out is the need for a comprehensive strategy that addresses the root causes of the outbreak, including the security issues and the displacement of tens of thousands of people. From my perspective, the funding for vaccine development is a necessary step, but it should be accompanied by a broader strategy that addresses the underlying issues. The technologies to make an efficacious Bundibugyo vaccine are available, but we need to do the work to demonstrate that they do work, and we need to do it quickly.
The IAVI vaccine, considered the most promising candidate by the WHO, is a step in the right direction. However, the timeline for clinical trials is a concern. The WHO expects it to take seven to nine months before doses of the rVSV Bundibugyo vaccine are ready for clinical trials, which is a long time in the context of an ongoing outbreak. Mark Feinberg, IAVI’s president, is right to point out that the world should have been more prepared, and I agree that we need to do better in the future as a global health community.
The Oxford vaccine, developed by Oxford University with the Serum Institute of India, could be available faster than IAVI’s candidate, with trials within two or three months. This is a positive development, but the WHO experts want to see more data from tests in animals to confirm its suitability. The use of the same technology as the Oxford/AstraZeneca Covid-19 jab is a plus, but we need to ensure that the vaccine is safe and effective.
The Moderna vaccine, which did not appear on the WHO’s candidate list, is another promising development. The company hopes it could be ready for trials within months, and CEPI has committed up to $50m to support preclinical development and early clinical testing. However, we need to ensure that the vaccine is safe and effective, and that it is accessible to the communities that need it most.
Three potential treatments, MBP134, Maftivimab, and remdesivir, are also in development. Amanda Rojek, associate professor of health emergencies at the UK’s Pandemic Sciences Institute, is working on the Partners trial, designed to find the most effective treatment. The drugs exist, and investigators are seeking regulatory approval from authorities in the DRC and Uganda. However, the key hurdle is ensuring that the drugs are safe and effective, and that the trial can be implemented safely in a challenging environment.
For the first time in an Ebola outbreak, doctors will test a prevention drug, giving it to contacts of cases to see if it stops them developing the disease. The antiviral drug obdeldesivir provided up to 100% protection in monkeys against two other strains of Ebola when given daily for 10 days, within 24 hours. However, the results will depend on the drugs’ effectiveness and the ability of teams on the ground to identify the right people to take part. The security situation in the affected regions is a significant challenge, and we need to ensure that the trial can be implemented safely and effectively.
In conclusion, the race to combat Ebola is a global effort, and the funding for vaccine development is a crucial step. However, we need to ensure that the vaccines and treatments are safe and effective, and that they are accessible to the communities that need them most. We also need to address the underlying issues, including the security situation and the displacement of people, to prevent future outbreaks. The challenges are significant, but with a comprehensive strategy and a commitment to global health, we can overcome them.
